Retrospective Analysis of Paediatric Glial Tumours that Required Modern Molecular Techniques.

Mehmet Arda Inan, Betul Ogut, Meral Toker, Ozge Nur Aricasoy, Ozge Vural, Pelin Kuzucu, Aylar Poyraz
{"title":"Retrospective Analysis of Paediatric Glial Tumours that Required Modern Molecular Techniques.","authors":"Mehmet Arda Inan,&nbsp;Betul Ogut,&nbsp;Meral Toker,&nbsp;Ozge Nur Aricasoy,&nbsp;Ozge Vural,&nbsp;Pelin Kuzucu,&nbsp;Aylar Poyraz","doi":"10.5137/1019-5149.JTN.44205-23.1","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To determine if previous histological grading systems were sufficient or unreliable with a limited repository of modern techniques.</p><p><strong>Material and methods: </strong>The pathology reports of pediatric neurosurgery patients between 2019-2022 were accessed. Data on patients that needed unattainable further molecular investigation were extracted. Data were noted from electronic archives, including their sex, age, histologic grade, location, resection type, survival, and therapy.</p><p><strong>Results: </strong>Out of 61 surgeries, 17 patients needed further investigation for a proper 2022 World Health Organization (WHO) diagnosis. Seven were deceased, and nine were alive. Two of 10 patients with low-grade gliomas and five of six patients with highgrade gliomas were deceased. Data on one foreign patient with high-grade glioma was inaccessible. The average survival was 9 months for the deceased.</p><p><strong>Conclusion: </strong>Modern molecular techniques such as next-generation sequencing and methylation profiling are the state-ofthe- art methods, but it is hard for developing and underdeveloped countries to utilize such methods. The classification schemes, diagnostic key figures, and treatment modalities are developed using these techniques, but the less developed world is incapable of achieving these. We are trying to hybridize the modern and classic modalities, and the results of our study show that for overall survival, there is still not much difference. More economic and feasible techniques should be produced and summarized for the rest of the world.</p>","PeriodicalId":94381,"journal":{"name":"Turkish neurosurgery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish neurosurgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5137/1019-5149.JTN.44205-23.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To determine if previous histological grading systems were sufficient or unreliable with a limited repository of modern techniques.

Material and methods: The pathology reports of pediatric neurosurgery patients between 2019-2022 were accessed. Data on patients that needed unattainable further molecular investigation were extracted. Data were noted from electronic archives, including their sex, age, histologic grade, location, resection type, survival, and therapy.

Results: Out of 61 surgeries, 17 patients needed further investigation for a proper 2022 World Health Organization (WHO) diagnosis. Seven were deceased, and nine were alive. Two of 10 patients with low-grade gliomas and five of six patients with highgrade gliomas were deceased. Data on one foreign patient with high-grade glioma was inaccessible. The average survival was 9 months for the deceased.

Conclusion: Modern molecular techniques such as next-generation sequencing and methylation profiling are the state-ofthe- art methods, but it is hard for developing and underdeveloped countries to utilize such methods. The classification schemes, diagnostic key figures, and treatment modalities are developed using these techniques, but the less developed world is incapable of achieving these. We are trying to hybridize the modern and classic modalities, and the results of our study show that for overall survival, there is still not much difference. More economic and feasible techniques should be produced and summarized for the rest of the world.

需要现代分子技术的儿童胶质瘤回顾性分析。
目的:现代分子技术的进步对中枢神经系统肿瘤的分类进行了广泛的修改。现代分子技术需要昂贵的基础设施、训练有素的专职人员以及获得良好的最佳组织。作为一家发展中国家的高等研究和教育医院,我们的现代技术储备有限,我们的目标是根据最新文献确定我们以前的组织学分级系统是否足够或不可靠。材料和方法:查阅2019-2022年小儿神经外科患者的病理报告。提取了需要进一步分子研究的患者数据。数据来自电子档案,包括他们的性别、年龄、组织学分级、位置、切除类型、生存率和治疗。结果:在61例手术中,有17名患者需要进一步调查,以获得2022年世界卫生组织(世界卫生组织)的正确诊断。七人死亡,九人活着。无法获得一名患有高级胶质瘤的外国患者的数据。10例低级别胶质瘤患者中有2例死亡,6例高级别胶质瘤病例中有5例死亡。死者的平均存活时间为9个月。结论:下一代测序和甲基化图谱等现代分子技术是最先进的方法,但发展中国家和欠发达国家很难利用这些方法。分类方案、诊断关键数字和治疗模式都是使用这些技术制定的,但欠发达国家无法实现这些目标。我们正在尝试将现代和经典模式杂交,我们的研究结果表明,就总体生存率而言,仍然没有太大差异。应该为世界其他地区制定和总结更多经济可行的技术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信